Key facts
- This page summarizes David D. Davidar's Form 4 filing for GLOBUS MEDICAL INC (GMED).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 21 Apr 2022, 17:00.
David D. Davidar - 19 Apr 2022 Form 4 Insider Report for GLOBUS MEDICAL INC (GMED)
- Reporting relationship
- Director
- Issuer ticker
- GMED
- Reported as of
- 19 Apr 2022
- Net transaction value
- -$2,458,071
- SEC form
- 4
- Accepted by SEC
- 21 Apr 2022, 17:00:54 UTC
- Prior SEC filing
- 18 Jan 2023
- Next SEC filing
- 27 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kelly G. Huller, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
David D. Davidar filed Form 4 for GLOBUS MEDICAL INC (GMED) on 21 Apr 2022.
Change
- Previous filing in this sequence was filed on 18 Jan 2023.
- Current net transaction value: -$2,458,071.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GMED
transaction
Class A Common Stock
Sale
- Transaction value
- $2,458,071
- Shares
- -31,500
- Change %
- -5%
- Price
- $78.03
- Shares after
- 601,275
- Date
- 19 Apr 2022
- Ownership
- Direct
- Footnotes
- F1, F2
GMED
holding
Class A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 205,967
- Date
- 19 Apr 2022
- Ownership
- By Davidar Family Irrevocable Trust U/A 8/6/09
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.15, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Footnote F3
These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is trustee of the trust.